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1. Introduction 
Renal transplantation is the preferred renal replacement therapy for patients with end 
stage renal disease (ESRD) as this modality provides better quality of life, improved 
overall survival, and lower treatment cost than dialysis. Malignancy is a known 
complication among transplant recipients, and is likely to become even more common in 
these patients as donation criteria are extended to allow older donors, the age of patients 
on waiting list is increased, and transplant recipients live longer (Gallagher et al, 2010). 
However still there is a continuous struggle to keep the delicate balance between reducing 
the immunosuppression and maintaining the graft survival. Majority of post-transplant 
morbidity and mortality is related to immunosuppression. Post-transplant patients are 
subjected to high rate of infections, medication nephrotoxicity, cardiovascular disorders, 
and development of malignancies. The life expectancy in kidney transplant patients is 
only half of that in general population. Although cardiovascular diseases are the most 
common cause of death in patients with functioning graft, malignancy is a significant 
cause of mortality. Malignancy is the third most common cause of death in renal 
transplant recipients after cardiovascular events and infections. There is a substantial 
three to five fold increase in the incidence of malignancy after solid organ transplantation 
as compared to the general population. Moreover the cancer incidence is also higher in 
transplant recipients than that seen in dialysis patients (Rama & Grinyó, 2010). As the risk 
of acute rejection and subsequent organ loss diminished due to the introduction of better 
immunosuppressive agents, infection and malignancy incidence has increased. Recently 
the life-threatening infections have also been declining due to the more judicious use of 
immunosuppressive agents and improved treatment regimen for infections. As 
cardiovascular diseases poses the greatest risk to the long-term graft and patient survival, 
efforts are being undertaken to reduce these risks by the use of less atherogenic 
immunosuppressive regimens, aggressive treatment of hyperlipidemia and better blood 
pressure control. Based on these observations it is estimated that malignancy will surpass 
cardiovascular complications as the leading cause of death post-transplant within the next 
2 decades (Buell et al, 2005). 
www.intechopen.com
 
Renal Transplantation – Updates and Advances 
 
180 
2. Epidemiology 
There are several factors that lead to development of malignancy among transplant 
recipients. These include impaired immunosurveillance of tumor cells, DNA damage and 
impaired DNA repair mechanism, exposure to oncogenic viruses, and upregulation of 
cytokines that may promote tumor growth such as vascular endothelial growth factor, 
transforming growth factor ┚1 (TGF-┚1), and  interleukin-10. Certain neoplasms have a 
much higher incidence in post-transplant patients such as skin cancers including squamous 
cell carcinoma, basal cell carcinoma, merkel cell cancer, and melanoma, kaposi’s sarcoma, 
lymphoma, carcinoma of oropharynx, anogenital cancer, liver cancer, in-situ carcinoma of 
cervix , renal cell carcinoma, and several sarcomas. In contrast,  solid tumors that are most 
commonly seen in general population such as breast, colorectal, prostate, and invasive 
cervical cancer have only a modest increase in post-transplant patients. The largest study on 
the rate and types of malignancies was on 35,000 first time renal transplant recipients of 
deceased and living donor kidney transplants. As compared to the general population, the 
incidence of tumors was found to be as follows (kasiske et al, 2004):  
 2 fold increase: most common solid tumors in general population such as breast, colon, 
prostate, lung, ovary, stomach, pancreas, and esophagus. 
 3 fold increase: testicular and bladder carcinoma. 
 5 fold increase: melanoma, leukemia, hepatobiliary, cervical, and vulvovaginal tumors. 
 15 fold increase: renal cell carcinoma. 
 20 fold increase: nonmelanoma skin cancer, non-Hodgkins lymphoma(NHL), and 
kaposi’s sarcoma (KS). 
Certain malignancies tend to occur at a higher rate in transplant recipients as compared to 
patients on transplant waiting list (Morath et al, 2004). These include non-melanoma skin 
cancer (2.6 fold), melanoma (2.2 fold), KS (9 fold) NHL (3.3 fold), oral cancer (2.2 fold), and 
renal cell carcinoma (39% higher) (Kasiske et al, 2004). Malignancy development is 2-4 fold 
more common in heart transplant than renal transplant patients as a result of increased 
immunosuppression required in heart transplantation. In general, the post-transplant 
carcinomas tend to behave more aggressively and have a worse outcome. The incidence of 
second primary cancer is similar to that of the first malignancy with an exception of non-
melanoma skin cancer with recurrent Squamous cell carcinoma. Malignancies develop in 15-
20% of transplant recipients after 10 years. After 20 years of immunosuppressive therapy, 
approximately 40% of recipients develop cancer. However the real incidence still could be 
underestimated as follow-up is usually short in many patients (Pita-Fernandez et al, 2009).  
The average latency of malignancy development after transplant is approximately 3-5 years. 
Different tumors have a distinct time interval between transplant and tumor presentation 
(Brennan et al, 2011): 
 Kaposi’s sarcoma : 13-21 months 
 Lymphomas: 32 months. The risk is highest during the first year when the 
immunosuppression is intense and the risk of viral infection is highest. 
 Epithelial carcinomas (including skin): 69 months 
 Anogenital region carcinomas: 84-112 months. The latency is longer in children 
transplant recipients who may develop tumors during adulthood. 
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3. Common malignancies in transplant recipients 
3.1 Skin carcinomas 
Non-melanoma skin cancers such as squamous cell and basal cell carcinomas are common 
after transplant. They account for approximately 37% of all cancers, and can result in 
significant morbidity and mortality rate of 5-8%. As compared to general population, the 
transplant recipients develop these tumors 15-20 years earlier with an average time of 
development of 4-9 years post- transplant. The incidence of these tumors can vary between 
different geographic locations. Risk factors include increase age, male gender, fair skin, HLA 
A11, B27, and DR7, presence of HPV, use of cyclosporine, or Azathioprin, sun exposure, and 
the geographic location. Rapamycin has been reported to potentially decrease the risk of 
developing these tumors after transplant (Comeau et al, 2008). The overall incidence of skin 
cancer rises progressively as transplanted graft longevity increases with a cumulative risk 
increase from 7.5% to 28.6% after 5 years and 15 years respectively. The anatomic 
distribution of these tumors in transplant recipients is similar to the general population. The 
development of skin cancer is also strongly related to the patient’s age and sex at the time of 
the transplantation (Naldi et al, 2000).  
3.1.1 Squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) 
Non-melanoma skin cancers are the commonest tumors following solid organ transplant. They 
are reported to occur approximately 8 years after renal transplant in recipients aged 40 years 
or younger, and 3 years post-transplant in recipients 60 years and older. SCC and BCC account 
for more than 90% of these tumors. The risk of SCC is 60-250 times greater than the general 
population whereas the risk of BCC is 10 times higher. Interestingly, SCC is more common 
than BCC in transplant patients which is in contrast to the general population where the ratio 
of BCC:SCC is 4:1. Both tumors generally occur at a younger age, involve multiple sites, 
behave more aggressively, and tend to recur after treatment. The most important risk factors 
are prior exposure to ultraviolet radiation, and for SCC, development of premalignant lesions 
such as Bowen’s disease, premalignant keratosis and warts, and keratoacanthoma. 
3.1.2 Melanoma 
The risk of developing melanoma is 3.6 times greater than in the general population. The 
risk is positively associated with increasing age at transplant, and use of depleting anti-
lymphocyte antibodies. On the other hand, increasing time since transplant, female sex, and 
non-Caucasian race are associated with a reduced risk of melanoma development.  
3.1.3 Merkel cell carcinoma (MCC) 
MCC is an aggressive neuroendocrine carcinoma of skin which has an even more aggressive 
outcome in transplant patients.it is more common in transplant recipients with an average 
of 7 years post-transplant and mean survival of 18 months after diagnosis. Merkel cell 
polyomavirus (MCV) is believed to be a contributing factor. 
3.1.4 Carcinomas of anogenital region 
The incidence of these tumors is 100 fold higher in renal transplant recipients. These tumors 
often present as pigmented maculopapular lesions or warts. They tend to involve multiple 
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sites including anus, and or perianal skin, and external genitalia of both sexes. They are 
usually extensive, in particular in women, one third of whom have concurrent cervical 
cancer. 
3.2 SCC of the eye 
The incidence of SCC of the eye is 20 fold higher in transplant recipients than in the general 
population. The incidence is also higher in HIV patients. 
3.3 Urinary tract malignacy 
There is an increased risk of developing tumors of the native urinary tract in patients with 
an exposure to cyclophosphamide, analgesic nephropathy, and nephropathy-induced by 
Chinese herbs (Morath et al, 2004).  
3.3.1 Renal cell carcinoma (RCC) 
The incidence of RCC after renal transplant is increased by more than 15 fold. Primary RCC 
occurs in approximately 3% of the general population, and 4.6% of renal transplant patients. 
The risk is increased in African-Americans, men, older donor age of more than 50 years, 
recipient age at least 65 years, patients with microscopic hematuria, acquired cystic kidney 
disease, analgesic nephropathy, and longer pre-transplant dialysis interval. More than 70 % 
of these tumors arise in native kidneys with only few cases reported in allografts. Once a 
RCC is diagnosed in an allograft, it is crucial to know the origin of the tumor cells whether 
they are of donor or recipient origin. RCC originating from renal allograft can be 
distinguished from RCC of the native kidney. Most RCCs of native kidney present as 
incidental tumors (90%) that are of low-grade, low-stage, and have a good prognosis. Post-
transplant RCCs, on the other hand, are multifocal in 40% of cases, and bilateral in 20%. 
Clear cell carcinoma is the most common subtype, although papillary subtype is seen more 
frequently than in non-transplanted patients. If the RCC develops 6 months after transplant, 
it is assumed to be de novo. Although multiple risk factors have been identified, the exact 
risk factor dependent screening protocol is yet to be determined (Klatte & Marberger, 2011, 
& Boix, et al, 2009, & Tydén et al, 2000). 
3.3.2 Bladder carcinoma 
Among the urologic malignancies that develop after transplant, bladder cancers are 
associated with worse prognosis, aggressive behavior, and high risk of recurrence than the 
general population. Most bladder carcinomas reported among solid organ transplant 
recipients are seen after kidney transplant. Yearly screening for non-glomerular hematuria is 
indicated in patients exposed to prolonged cyclophosphamide therapy due to the increased 
risk of bladder cancer. These patients should undergo cystoscopy as cytology may miss low 
grade lesions.  
3.4 Lung carcinoma 
In comparison to renal and liver transplant recipients, the incidence of lung tumors tends to 
be much higher in heart and lung transplant patients.  
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3.5 Kaposi’s sarcoma (KS) 
The incidence of KS is much higher in renal transplant recipients with a male predilection 
(male:female ratio of 3.3:1). It is caused by Human Herpes virus 8 (HHV-8) and is commonly 
seen in patients of Mediterranean, Arabic, Jewish, Caribbean, or African descent, mostly 
corresponding to the geographic distribution of HHV-8. The choice of immunosuppressive 
agent also plays a role in development of this entity as calcineurin inhibitors are associated 
with a higher risk of developing KS than other immunosuppressive agents. Clinical 
presentation is similar to the classic KS with angiomatous lesions involving the lower 
extremities. Approximately 90% of patients have cutaneous involvement with 10% showing 
visceral involvement which is associated with a worse prognosis. The incidence of visceral 
involvement is lower in renal transplant than in heart or lung transplant recipients. 
3.6 Gastrointestinal (GI) carcinomas 
Approximately 50% of GI malignancies affect the large intestine. Other organs at increased 
risk are liver, esophagus, and stomach (Lutz & Heemann, 2003). Colorectal carcinomas 
occur almost 3 times more frequently in renal transplant than age- and gender- matched 
general population. Significant risk factors include male gender, > 50 years of age, and the 
duration of immunosuppression (Nafar et al, 2009). GI malignancies have poor prognosis. 
Cancer survival by stage is also much worse in transplant recipients. The 5 year survival for 
localized cancer is 74% in transplant patients as compared to 90% in the general population. 
3.6.1 Hepatocellular carcinoma 
Infection with oncogenic hepatitis B and C viruses increases the risk of hepatocellular cancer. 
Transplant recipients with known hepatitis B and C cirrhotic liver disease should have serum 
alpha-fetoprotein (AFP) and hepatic ultrasound screen every 12 months (Kasiske et al, 2010). 
AFP has high specificity (>90%) but low sensitivity (20-60%) for detection of small 
hepatocellular carcinomas. The abdominal ultrasound, on the other hand, is more sensitive 
than serum AFP (80-85%) for detection of small hepatocellular carcinoma (1-5 cms in size). 
Patients with suspicious lesions should undergo contrast-enhanced CT (Brennan et al, 2011). 
3.7 Post-transplant lymphoproliferative disorder (PTLD) 
PTLD is characterized by abnormal proliferation of lymphoid cells with majority 
representing malignant lymphoproliferative lesions. The most recent 2008 WHO 
classification of PTLD stratifies the subgroups into monoclonal or polyclonal. These are 
further subdivided according to their morphologic features and characteristics to 
monomorphic, if cells are homogenous, or polymorphic if cells are heterogenous. (Table 1) 
(Mucha et al, 2010). PTLD varies from polyclonal B cell proliferation with normal 
cytogenetics and no evidence of immunoglobulin gene rearrangement to polyclonal B cell 
proliferation with early malignant transformation associated with clonal cytogenetic 
abnormalities and or immunoglobulin gene rearrangements to monoclonal B cell 
proliferation with malignant cytogenetic abnormalities and immunoglobulin gene 
rearrangements, the latter accounting for about 15% of cases (Nalesnik et al, 1988). 80-90% of 
these PTLDs representing B-cell malignancies are associated with EBV infection. Most 
PTLDs are of recipient origin with only few that are of donor cell origin. The recipient-origin  
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Early Leions  Plasmacytic Hyperplasia 
 Infectious-mononucleosis like lesions 
Polymorphic PTLD  
Monomorphic PTLD  B Cell Neoplasms 
o Diffuse large B-cell lymphoma 
o Burkitt lymphoma 
o Plasma cell myeloma 
o Plasmacytoma-like lesions 
 T Cell Neoplasms 
o Peripheral T-cell lymphoma, not 
otherwise specified 
o Hepatosplenic T-cell lymphoma 
Classical Hodgkins 
Lymphoma-type PTLD 
 
Table 1. Pathologic Classification of PTLD (Morgans et al, 2009). 
PTLDs clinically present with a multisystem disease that occurs after an average of 76 
months post-transplant. On the other hand, the donor-origin PTLDs are usually limited to 
the allograft, develop after an average of 5 months, and regress with reduction of 
immunosuppression. Although, most of these disorders are of B-cell origin, however T-cell 
derived lesions are rarely reported. Data obtained from United States Renal Data System 
related to 66,159 renal transplant recipients, reported the development of malignant 
lymphoid proliferation in 1.8% of patients over 10 year follow-up, with 70% representing 
NHL, 14% multiple myeloma, 11% lymphoid leukemias, and 5% Hodgkins lymphoma (HL) 
(Caillard et al, 2006). The incidence was higher in the first year. NHLs in these patients have 
a more aggressive clinical course with more extranodal involvement occurring in 30-70% of 
cases, and worse prognosis. The lymphoproliferative disorders occurring in post-transplant 
behave differently than those in general population. NHL accounts for 65% of lymphomas 
in the general population whereas it accounts for 93% in post-transplant patients. Most of 
these NHLs are large cell lymphomas, majority of B-cell origin. For early detection of these 
disorders, a high level of suspicion is required, and when diagnosed the management 
should be handled by an experienced team to overcome this life-threatening complication 
(Morgans et al, 2009). Although the prognosis varies with clonality and extent of disease, the 
overall survival rate ranges from 25-35%. Mortality with monoclonal malignancies has been 
reported to be as high as 80%. T cell lymphomas in general have an extremely poor 
prognosis. Additional prognostic factors associated with worse outcome are identified for 
PTLD that include the performance status of > 2 as per the Eastern Cooperative Oncology 
Group criteria and more than one site involvement. The International Prognostic Index 
useful in determining prognosis in immunocompetent patients with NHL, is less beneficial 
in this setting. Adverse prognostic indicators include the presence of hypoalbuminemia, and 
involvement of central nervous system (CNS) and bone marrow. Increase mortality rates 
have been associated with a diagnosis within 6 months versus after 6 months from surgery 
(64% versus 54%), increasing age, no surgical intervention (100% versus 55%), allograft plus 
other organ involvement versus allograft involvement alone (64% versus 31%), and multiple 
versus single sites (73% versus 53%) and the risks are additive (Friedberg et al, 2011). 
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4. Pathogenesis 
Malignancy can develop in transplant recipients in three different ways (Morath et al, 2004): 
 De novo malignancy occurrence. The risk is approximately 0.2%. 
 Recurrent malignancy in the recipient.  
 Transmission of malignancy from the donor. Despite all efforts to secure a safe organ 
for transplantation, transmission of diseases such as malignancies, and infections may 
occur. Donor transmission of solid cancers is an unlikely event (Pedotti et al, 2004). 
These tumors may represent metastasis from malignancies diagnosed in the donor at 
the time of transplant (Donor-transmitted malignancy) or tumors develop de novo in 
transplanted donor tissue (Donor-derived malignancy). The risk of cancer developing 
in recipients receiving kidney from a donor with known or incidentally discovered 
cancer is 45%. In a population based study by the United Network for Organ Sharing 
analysed 257 donors who donated 650 organs over a period of 33 months (Birkeland & 
Storm, 2002 ), both cadaveric and living-related donors were seen to have a concealed 
malignancy. In general, diagnosis of a malignant tumor in a donor is a contraindication 
for organ donation, except from those with in-situ carcinoma of cervix, low-grade 
cancers of skin, and primary tumors of CNS. CNS tumors may metastasize in less than 
2.3% of cases with only few reports of transmission to recipients (Detry et al, 1997 & 
2000 & Wallace et al, 1996). 
4.1 Risk factors 
Multiple factors are associated with development of de novo malignancy in transplant 
recipients. The risk of oncogenesis after transplantation is related to the types and duration 
of exposure to immunosuppressive therapy. Disruption of both antitumor immune 
surveillance and antiviral activity likely play a role. Chronic antigen stimulation from 
transplanted organs, repeated infections, or transfusion of blood products may overly 
stimulate a partially depressed immune system, resulting in the development of post-
transplant lymphoproliferative disorder (Buell et al, 2005, Chapman and Campistol, 2007). 
4.1.1 Immunosuppression 
There is strong evidence that the intensity of immunosuppression after transplant affects the 
risk of post-transplant malignancy development. This observation is supported by the fact 
that the incidence of malignancy is higher in heart and lung transplant patients who 
routinely require more intense immunosuppression than renal transplant recipients. In 
addition, the risk of development of PTLD is highest in the first year post-transplant when 
the degree of immunosuppression is at its maximum. Episodes of graft rejection in the first 
year post-transplant increase the likelihood of developing a second malignancy most likely 
due to the increased level of immunosuppression required. 
4.1.1.1 Calcineurin inhibitors (CNI) 
Both cyclosporine and tacrolimus have been associated with increased levels of TGF-┚ that 
might lead to tumor growth since both agents have long been linked to the development of 
post-transplant malignancies including PTLD and solid organ cancers. Some authors suggest 
that tacrolimus is safer than cyclosporine in this regards. In addition, cyclosporine also 
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induces production of VEGF, thus promoting carcinogenesis, and enhances the apoptotic 
effect of taxol and INF-gamma on human gastric and bladder carcinomas (Buell et al, 2005). 
Patients receiving low dose cyclosporine have a lower incidence of malignancy development 
(19.8% versus 32%) in particular skin carcinomas. In animal model, cyclosporine and 
tacrolimus have a direct effect on the tumor cells, promote invasiveness, and facilitate 
metastases. Data suggest that the CNI promote metastatic spread of the pre-existing tumor 
cells rather than convert a non-malignant cell into a cancer cell (Suthanthiran, 2009). 
4.1.1.2 Azathioprin 
Azathioprine is an antimetabolite that has long been recognized as an etiologic agent in the 
development of neoplasia. It is in particular associated with increased incidence of non-
melanoma skin cancer especially SCC. It also may lead to the development of 
myelodysplastic syndrome. Azathioprin has been reported to increase photosensitivity and 
also allows ultraviolet A to directly damage the DNA by intercalating DNA level, inhibiting 
repair splicing, eliciting codon misreads, and development of microsatellite DNA instability 
(Buell et al, 2005 & O’Donovan et al, 2005). 
4.1.1.3 Antilymphocyte therapy 
The use of anti-T-cell therapy (antilymphocyte serum or muromonab-CD3), but not IL-2 
receptor antibodies, has been shown to predispose solid organ transplant recipients to EBV-
associated PTLD. Transplant patients on monoclonal antilymphocyte antibody (anti-CD3) as 
the sole induction agent, show a 72% increase in in the risk of PTLD, however despite this 
relation anti-CD3 has not been found to show any association in the development of other 
solid organ malignancies. Anti-CD52 appears safer with no increased risk of de novo 
malignancy development (Buell et al, 2005). 
4.1.1.4 Sirolimus 
Sirolimus, an inhibitor of the mammalian target of rapamycin (m-TOR), suppresses the growth 
and proliferation of tumors. It has antineoplastic effect mainly due to inhibition of p70 S6K, IL-
10, cyclins, and vascular endothelial growth factors A and C, with direct inhibition of cell 
replication, induction of apoptosis, and inhibition of tumor angiogenesis. Some studies show a 
decreased incidence of malignancy in patients receiving Sirolimus than other 
immunosuppressive therapies. Post-transplant patients treated with Sirolimus appear to have 
a lower incidence of de novo malignancy when compared with a triple immunosuppressive 
regimen treated group (CNI, antimetabolite, and corticosteroids). In addition the use of 
Sirolimus in place of cyclosporine has been associated with complete regression of KS in the 
vast majority of renal transplant recipients (Buell et al, 2005). Newer sirolimus analogues, such 
as temsirolimus, have become a focus in pure oncological research for their antineoplastic 
effects on a variety of malignancies (Kapoor, 2008, & Campistol, 2007). 
4.1.1.5 Mycophenolate Mofetil (MMF) 
MMF impairs lymphocyte function by inhibiting enzyme inosine monophosphate 
dehydrogenase leading to purine biosynthesis block. Several cancers including leukemias 
and some solid tumors produce dramatic elevation of this enzyme. Some studies suggest 
that the risk of malignancy is not increased and even may be even decreased with MMF 
(Rama & Grinyó, 2010 & Brennan et al, 2011). Recent studies show a distinctive 
antineoplastic effect of MMF against colorectal and prostatic carcinomas, and its inhibiting 
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effect on the adhesion of colonic adenocarcinomatous cells to endothelial cells (Eng, 2005, & 
Leckel, 2003). The use of MMF is clearly associated with a distinctive decrease in the 
incidence of post-transplant PTLD (Buell et al, 2005).   
4.1.2 Conventional risk factors 
Exposure to ultraviolet radiation is associated with increased risk of skin cancer. Other 
common risk factors are also associated with development of post-transplant malignancy 
such as advanced age, smoking, and analgesic abuse. History of phenacetin abuse is 
associated with striking increase in urothelial carcinoma. Renal transplant recipients also 
have higher incidence of development of carcinomas in the native kidneys in particular if 
they have been on long term dialysis. The incidence is almost 100 times greater than 
expected and is in part related to ESRD, tubular hyperplasia, cyst formation, and in some 
cases malignant transformation.  
4.1.3 Genetic factors 
Transplant recipients who had history of invasive carcinoma before transplant have a higher 
risk (relative risk 2.38) of developing a second invasive carcinoma post-transplant. Some 
primary renal disorders such as von Hippel-Lindau disease are associated with higher risk 
of developing renal cell carcinoma that behave more aggressively. In addition, patients with 
Wiskott-Aldrich syndrome and Drash syndrome are also associated with an increased risk 
of carcinoma development in particular lymphoma and Wilms tumor.  
4.1.4 Coexisting oncogenic viral infection 
Certain viral infections are associated with increased predisposition of transplant patients to 
development of specific tumors. At least 4 viruses may be cocarcinogenic in transplant 
patients.  
4.1.4.1 EBV 
Most PTLDs are associated with EBV infection. EBV is a gamma herpes virus. It is present 
worldwide and EBV antibodies are seen in almost 90-95% of the population. In 
immunosuppressed patients, EBV infection can lead to cell transformation. Latent 
membrane protein-1 (LMP-1) of EBV has the major role in EBV-associated PTLD 
development as it engages the signaling proteins from tumor-necrosis-factor-receptor-
associated factors (TRAFs) that lead to cell growth and transformation. There is increased 
risk of PTLD among EBV-seronegative recipients of EBV positive donors. The incidence of 
PTLD for EBV seronegative recipients is reported to be 24 times higher than EBV 
seropositive recipients. EBV negative PTLDs present much later (2324 days versus 546 days 
post-transplant), and have a much more virulent behavior (Friedberg et al, 2011). 
4.1.4.2 HHV-8 
All types of KS including classic, endemic, AIDS-related, and post-transplant KS are all 
associated with HHV-8 presence in tumor tissue. There is convincing evidence of 
transmission of HHV-8 from the donor to transplant recipients, with one study showing 
evidence of donor-derived tumor cells transmitted to transplant recipients. HHV-8 is 
necessary but not sufficient for KS development, with transplant related immune  
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dysfunction being an important contributing cofactor. Pretransplant antibody screening of 
recipients as well as donors in high seroprevalent areas may be useful. However 
seropositivity for HHV-8 is not always associated with increased risk of development of KS. 
Studies from Saudi Arabia show the proportion of patients with antibodies against HHV-8 
is higher among patients who developed KS post-transplant than those who did not. In 
addition the incidence of KS is higher in patients with HHV-8 infection at the time of 
transplant than among those who did not have infection (15-28% versus <1%) (Diociauiti et 
al, 2000, & Cattani et al, 2001, & Regamey et al, 1998). A study from Saudi Arabia revealed 
10 fold higher incidence of KS in Saudi transplant recipients than in Western countries. In 
addition, there was a markedly higher incidence of specific anti-HHV-8 antibodies in 
patients with KS as compared to those without it (92% versus 28%) (Qunibi et al, 1998). 
4.1.4.3 Human papilloma virus (HPV) 
There is an extremely diverse group of HPV subtypes that can be found in various benign, 
premalignant, and malignant skin lesions in transplant recipients. Multiple subtypes can be 
seen in a single lesion. HPV DNA is detected in 65-90% of skin tumors in transplant 
recipients. However a causative role of HPV in development of secondary skin cancers is 
not proven. Interestingly, HPV has been detected in normal hair follicles of transplant 
patients (Boxman et al, 1997, & Berkhout et al, 2000). 
4.1.4.4 Merkel cell virus (MCV) 
MCV is believed to be a contributing factor to MCC.  
4.1.5 Geographic differences 
Literature review shows widely variable relative frequency of the different types of post-
transplant malignancies in different geographic areas. In Saudi Arabia the most common 
tumors in transplant recipients are KS, skin cancers (melanoma being more common in 
children than in adults), anogenital cancers, and lymphomas particularly in children (al-
Sulaiman & al-Khader, 1994). In Japan the most common post-transplant tumors are those of 
digestive tract including stomach, liver, colon, and rectum. On the contrary, the incidence of 
lymphoma and skin tumors in Japan is low. In Australia the risk of skin cancer development is 
the highest, most likely due to the excessive sun exposure of the fair-skinned population. In 
South East Asia the frequency of liver cancer is high where hepatitis B and C infections are 
endemic. In United Kingdom lymphomas, renal cell carcinomas, bronchial cancer, and tumors 
of digestive tract are the most commonly encountered tumors in post-transplant recipients 
(Morath et al, 2004). In South Africa, the incidence of post-transplantation malignancy 
development is reported to be 5.6%, the commonest tumors being PTLD, followed by non-
melanoma skin cancer, KS, gastrointestinal carcinoma, cervical cancer, and vulval cancer 
(Maharaj & Assounga, 2010). The Northern Italy Transplant program studied 3,521 patients 
over a 10 years period in 10 local Transplant centers. The average cancer incidence was 4.9%. 
The commonest tumors were KS, PTLD, renal and skin cancers followed by colorectal, breast, 
gastric, lung, and bladder carcinomas, and mesothelioma (Pedotti et al, 2003). In India, the 
incidence of malignancy after transplant is lower than the Western countries. PTLD is the 
commonest malignancy there especially in the first year followed by oropharyngeal cancer. 
Skin cancer incidence of both melanoma as well as non-melanoma cancer is much lower 
mostly attributed to the high cutaneous melanin content (Joshi and Jha, 2009).  
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4.1.6 Renal transplant tourism 
Despite the international abandonment of commercial organ trafficking, many patients 
continue to travel to different countries to receive commercial transplants. Commercial 
cadaveric renal transplant was compared to domestic cadaveric renal transplant in China. 
The 10 year cumulative cancer incidence of the touring group, primarily of Taiwan origin, 
(21.5%) was significantly higher than the domestic group (6.8%). This might be related to 
older age at transplantation, more depleting antibody induction therapy, and omitted pre-
transplant cancer screening. The graft and patient survival in transplant tourism group is 
inferior as compared to the domestic group. Hepatocellular and urothelial carcinoma were 
the most prevalent malignancies in renal transplant tourism patients from Taiwan when 
compared to Western patients. This can be explained by the high incidence of viral hepatitis 
in Taiwan and the use of Chinese herbal medications. The use of Chines herbal medications 
containing anistolochic acid, which is associated with urothelial carcinoma development, 
facilitates diuresis and is a common practice in ESRD patients who do not accept dialysis. It 
is interesting that transplant tourism is considered to be an independent risk factor for post-
transplant malignancy development (Tsai et al, 2011).  
4.1.7 Blood groups 
Types of blood groups does not seem to be related to increased incidence of cancer 
development (Pedotti et al, 2003). 
4.1.8 Transplant center selection 
Selection of a particular transplant centers does not appear to be related to an increase in  
incidence of cancer development (Pedotti et al, 2003). 
4.1.9 HLA match 
There is a strong influence of HLA matching on graft outcome (Opelz, 2001). However the 
association is indirect and related to the aggressive immunosuppression required for low 
degree HLA matching.  
5. Incidence of post-transplantation malignancy in children 
The pattern of malignancies that occur in pediatrics post-transplant population is different 
from the adult post-transplant patients and the general pediatric population. In a study of 
219 children who underwent renal transplant, 7.3% developed malignancy. The 
cumulative incidence of cancer development was found to be 1.9% at 1 year, 4.0% at 5 
year, 6.9% at 10 years, and 10.2% at 15 years. The 10 years incidence of PTLD was 4.5% 
when the mortality rate was 25%. Other commonly encountered tumors in post-transplant 
children recipients are HL, Burkitt lymphoma, renal papillary carcinoma, thyroid 
papillary carcinoma, recurrent ovarian seminoma, and skin cancer. The occurrence of skin 
cancer is rare in children and usually occurs during early adulthood. Screening and early 
detection of these tumors in children is of great importance. In addition regular screening 
for EBV viral load is recommended for patients at risk for developing PTLD 
(Koukourgianni et al, 2010). 
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6. Transplantation in patients with pre-existing malignancy 
The recurrence rate of malignancy is 22% in patients treated before transplantation and 27% 
in those treated after transplantation. There is however variability in recurrence rate 
according to the type of tumor (Barrett et al, 1993, & Trofe et al, 2004, & Kasiske et al, 2001): 
 0-10%: Localized renal cell carcinoma, cervical, testicular, and thyroid carcinoma, and 
Hodgkins as well as non-Hodgkins lymphoma. 
 11-25%: Wilm’s tumor, and cancer of colon, uterus, prostate, and breast. 
 Over 25%: Advanced renal cell carcinoma, bladder cancer, myeloma, sarcoma, and skin 
cancer including melanoma and non-melanoma skin tumors.  
Patients with low risk tumors such as in-situ carcinoma, low grade bladder carcinoma, and 
basal cell carcinoma should have no waiting period for transplantation. Patients with 
tumors that have a high risk of recurrence such as melanoma, colorectal and breast cancer 
should wait for at least 5 years before translantation. For most other tumors a delay of 2 
years is often considered sufficient (Table 2) (Morath et al, 2004).  
Type of Cancer Recommendation (years) 
Breast cancer > 5 (> 2 for early disease) 
Colorectal cancer > 5 (> 2 for Dukes Stage A or B1) 
Melanoma > 5 (> 2 melanoma in situ) 
Uterine cervical cancer > 2 (> 5 for more advanced cervical cancer) 
Renal cell 
carcinoma/Wilms tumor 
> 2 (> 5 for large cancers; no wait for 
incidental tumor < 5 cm) 
Bladder cancer > 2 
Kaposi sarcoma > 2 
Leukemia > 2 (limited data to make 
recommendation) 
Lung cancer > 2 
Lymphoma > 2 (possibly > 5) 
Prostate cancer > 2 ( possibly less for localized disease) 
Testicular cancer > 2 
Thyroid cancer > 2 
Skin (nonmelanoma) cancer 0-2 (no wait for basal cell carcinoma) 
Liver cancer Unable to give recommendation 
Myeloma Unable to give recommendation 
Table 2. Recommended Wait Time (Years) Based on Type of Cancer Before Listing for 
Transplantation (Kasiske et al, 2001). 
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7. Multiple independent primary cancers or second tumor in transplant 
recipients 
Excluding the non-melanoma skin cancers, the risk of developing a second primary cancer is 
almost the same as the incidence of first cancer. The risk of developing a second primary in 
this group could be related to persistence of environmental risk factors associated with the 
first cancer such as tobacco, genetic factors responsible for development of second primary 
cancer, and individual susceptibility to carcinogens. A study of a network of cohort of 
transplanted patients shows the incidence of second primary cancer development to be 
0.3%. The incidence of developing second primary cancer is 1-5%. Excluding skin cancers, 
transplant patients with first cancer diagnoses should follow regular screening procedures 
and do not appear to require a special program (Taioli et al, 2006). 
Skin cancer is the commonest second malignancy among transplant recipients (Morath et al, 
2004). The North Italy Transplant program reported the prevalence of second primary 
cancer to be 1.7% and development of multiple independent primary cancers arising in the 
same patient to have a prevalence of 3.6% (Pedotti et al, 2003). The risk of developing a 
second non-melanoma skin cancer is high in renal transplant recipients who developed a 
first non-melanoma skin cancer. The risk is, in particular, high of SCC but is also 
substantially increased for BCC. The risk is much lower for SCC in renal transplant 
recipients who present with BCC, however after the diagnosis of first SCC the subsequent 
risk for SCC appears to be the same. The 3 year cumulative risk is approximately 59% of 
non-melanoma skin cancers and 62% of subsequent SCC. The 3 year risk of BCC is 37% and 
the 5 year risk of subsequent BCC is 51%. Renal transplant recipients who develop SCC 
mostly develop SCC as subsequent skin cancer and recipients who have BCC as first 
malignancy mostly develop subsequent BCC. This difference could be related to the 
difference in the lifestyle as the risk of SCC is associated with chronic cumulative sun 
exposure whereas BCC is more associated with intermittent intense sun exposure. Longer 
time between transplantation and development of first SCC is also associated with an 
increased risk of subsequent SCC. The type of maintenance immunosuppression is the most 
important risk factor of subsequent development of SCC. Patients on Azathioprin have an 
approximately 3 times higher risk of subsequent SCC as compared to cyclosporine-based 
regimen. The duration of immunosuppression also influences the development of 
subsequent SCC after the first SCC. Sun exposure is an important risk factor for multiple 
lesions development. Fair skin of patients and light color of the hair and the eyes are 
predictive of multiple SCC development (Euvrard et al, 2006). Male sex is also a risk factor 
for multiple skin cancer development, especially the BCC. In addition, BCC is more 
commonly seen in living-related kidney transplant than the cadaveric kidney transplant 
recipients (Wisgerhof et al, 2010). 
8. Prevention and screening for early detection 
Regular cancer screening is recommended when a patient is considered for renal transplant. 
Screening and early detection of cancers should be incorporated into the pre-transplant 
evaluation of ESRD patients. Screening may also detect premalignant lesions quite early 
allowing for a timely intervention (Kiberd, 2005). The rising age and the prolonged duration 
on transplant waiting list increases patients’ risk of being transplanted with an undetected 
malignancy (Morath et al, 2004). Careful screening should be performed for the recipient as  
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Target Organ or 
Cancer 
Test* Frequency Age of Screening 
Breast Mammography Every 1-2 years > 40 years 
Colon/rectum Occult blood 
and 
Sigmoidoscopy 
or 
Colonoscopy 
Annually 
 
Every 5 years 
 
Every 10 years 
> 50 years 
 
> 50 years 
 
> 50 years 
Prostate gland Digital rectal exam 
PSA 
Annually > 50 years 
Kidney Imaging study† Once All patients 
Bladder Cystoscopy Not routine > 50 years and all high-
risk patients 
Uterine cervix Pap smear 
Pelvic exam 
Every 1-3 years > 20 years or any 
sexually active patient 
Testicle History and physical exam Once All male patients 
Kaposi sarcoma History and physical exam
HHV-8 assay 
Once All patients 
All high-risk patients 
Skin History and physical exam Once All patients 
Melanoma History and physical exam Once All patients 
Liver Imaging study† Once, high risk 
annually 
All patients 
Lung CXR Once All patients 
Lymphoma History and physical exam
EBV assay 
Annually All patients 
Leukemia CBC Annually All patients 
Myeloma Immunoelectropheresis Once > 50 years 
PSA = prostate specific antigen; HHV-8 = human herpes virus 8; CXR = chest x-ray;  
EBV = Epstein-Barr virus; CBC = complete blood count 
*Abnormalities on screening tests may indicate the need for additional tests. For example, suspicious 
lung lesions on the chest x-ray should be followed up with a computed tomography scan. 
†Ultrasound, CT scan, or magnetic resonance imaging scan. 
Table 3. Possible Pretransplant Screening Strategies for the Potential Kidney Transplant 
Recipient (Kasiske et al, 2001). 
well as the donor. The 2009 Kidney Disease: Improving Global Outcomes (KDIGO) clinical 
practice guidelines on monitoring and treatment of kidney transplant recipients were 
developed to help practitioners caring for these patients. These guidelines were based on 
evidence and systemic review of treatment trials. A set of recommendations were developed 
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for screening and risk assessment of renal transplant recipients (Kasiske et al, 2010). Patients 
with failed transplant returning to dialysis have a higher mortality than those on transplant 
waiting list (Cattran & Fenton, 1993).  
The Clinical Practice Guidelines Committee of the American Society of Transplantation 
(AST) has published guidelines for outpatient evaluation of pediatric and adult kidney 
transplant candidates that include recommendations for screening and early detection of 
malignancies. Some of these recommendations are represented in Tables 3 and 4 (Kasiske et 
al, 2001 & Kiberd, 2005, & Kalble et al, 2009, & AST Kidney-Pancreas committee, 2009). 
 
Target Organ or 
Cancer 
Who Test* Frequency Age of Screening 
Breast Selected* Mammography Every 1-2 
years 
> 40 years 
Colon/ rectum Selected* Occult blood 
and 
Sigmoidoscopy 
or 
colonoscopy 
Annually 
 
Every 5 years 
 
Every 10 
years 
> 50 years 
 
> 50 years 
 
> 50 years 
Prostate gland Selected† Digital rectal 
exam 
PSA 
Annually > 50 years 
Uterine cervix Female Pap smear 
Pelvic exam 
Every 1-3 
years 
> 20 years or any 
sexually active 
patients 
Kaposi sarcoma All History and 
physical 
Annually All high-risk 
patients 
Nonmelanoma 
skin 
All History and 
physical 
Annually All patients 
Melanoma All History and 
physical 
Annually All patients 
Liver Selected‡ Imaging study High risk 
annually 
All patients 
Lymphoma All History and 
physical 
As clinically 
indicated 
All patients 
PSA = prostate specific antigen 
*Patients with good life expectancy and good allograft function 
†Male patients at high risk, including black patients 
‡Patients with cirrhosis 
Table 4. Posttransplant Screening Strategies for the Kidney Transplant Recipient (Kiberd, 
2005). 
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8.1 Skin and lip cancer 
Introduction of patient education programs is recommended in particular in countries with 
high incidence of non-melanoma skin carcinoma secondary to high sun exposure. Patients 
should also be educated about their increased risk of such cancers especially if they are fair 
skinned, have high sun exposure level, or have prior history of skin cancer. Patients should 
reduce their sun exposure, perform self-examination, and have an annual skin and lip 
examination by qualified Health care provider. Oral acitretin should be given to patients 
with prior history of skin cancer to prevent development of new malignancy. 
8.2 Non-skin cancer 
The recommendations for transplant patients with moderately increased risk of developing 
non-skin cancer are non-specific. However they reinforce the same recommended screening 
strategies as for the general population. These include pap smear, self-breast examination, 
mammography, and colonoscopy. In addition annual liver ultrasound and ┙-fetoprotein 
monitoring is also recommended in patients with cirrhosis ((Rama & Grinyó, 2010). 
8.3 PTLD 
Since development of PTLD is related to the degree of immunosuppression, and infection 
with EBV and CMV, prevention largely relies on limiting patient exposure to aggressive 
immunosuppression, and anti-viral prophylaxis. There is a relatively high incidence of 
PTLD reported with introduction of tacrolimus and therefore rapid tapering of tacrolimus 
may limit the development of PTLD (Friedberg et al, 2011). In one review of PTLD in 
children, the incidence of PTLD development was 17% in children who received renal 
allograft with tacrolimus as compared to 4% in children who underwent aggressive tapering 
of tacrolimus (Shapiro et al, 1995). There is higher incidence reported of PTLD among EBV-
seronegative recipients of EBV-seropositive donors that suggests that treatment of early EBV 
infection may decrease subsequent development of PTLD (Holmes et al, 2002 & Funch et al, 
2005). In addition prophylactic antiviral therapy is also associated with a reduced risk of 
PTLD development. The use of prophylactic anti-CMV during the first 3-6 months after 
renal transplant significantly reduces the incidence of PTLD in the first year post-transplant 
but not in the subsequent 5 years (Kasiske et al, 2010, & Opelz et al, 2007).  
8.4 Colorectal carcinoma 
Community-level screening for colorectal carcinomas using fecal occult blood is now a 
standard practice in most developed countries. Studies in the general population have 
shown that the benefits of starting screening at a younger age were little and costly as 
compared to starting at age of 50. However renal transplant patients have an age-shifted 
increase in the risk of colorectal carcinoma and screening at a younger age in this population 
seems therefore justifiable (Wong et al, 2008). 
9. Treatment 
Reduction or cessation of immunosuppression is particulary useful in renal transplant 
recipients as loss of graft secondary to rejection is not a fatal event in this group as 
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compared to the heart, lung, or liver transplant recipients. Immunosuppression reduction 
may lead to spontaneous regression of some tumors such as some cases of PTLD, some 
skin cancers, KS, and donor-derived malignancies. In KS reduction of CNI may be 
particularly important. Despite the association of CNI and cancer development, some 
authors recommend discontinuation of antimetabolite and use of CNI and Prednisone as 
first line approach in transplant recipients with malignancy. This is because rejection is 
less likely to occur with double therapy (CNI and prednisone) than combination of 
antimetabolite and prednisone. An exception to this is the very well matched HLA 
transplant recipients with 0 HLA, B, or DR mismatch, in which the risk of rejection is low 
with the use of antimetabolite in combination with prednisone (Brennan et al, 2011, & 
Bosman and Verpooten, 2007). 
9.1 Skin, non-melanoma carcinomas 
Once a skin lesion is detected there is no evidence of benefits from stopping azathioprin . 
Treatment of these patients requires several strategies including preventive strategy, specific 
treatment, and medical adjunct therapy because these tumors may present with multiple 
lesions, and large areas of skin involvement. Despite this, dedicated surveillance programs 
are lacking for most patients. Surgery remains the mainstay of managing these tumors and it 
may be destructive in large or multiple skin tumors. Studies in immunocompetent patients 
show recurrence in almost 100% of cases with incomplete surgical excision and therefore 
tumors that are not completely excised should be treated by additional methods (Jemec & 
Holm, 2003). 
9.1.1 SCC 
Premalignant lesions can be treated with topical retinoids or in combination with low 
dose systemic retinoids. Although systemic retinoids reduce actinic keratosis and prevent 
development of new dysplastic lesions in transplant patients, the treatment is frequently 
discontinued due to drug adverse events such as mucocutaneous xerosis, pruritis, 
arthralgia, and hyperlipidemia. Once treatment is discontinued, the lesions tend to recur 
rapidly. Superficial cancers can be treated with cryotherapy or electrocautery and 
curettage. More aggressive local therapy is required for invasive SCC as they may have 
metastasis at presentation and are more likely to develop recurrence. These invasive 
tumors need surgical excision with negative margins. Although there are no clear 
established guidelines about margins of SCC excision, Mohs micrographic surgery is 
typically recommended for these high risk tumors especially those seen in cephalic 
location, a diameter of > 2 cms, or rapid growth. Metastasis in a single lymph node is 
considered potentially curable. Adjuvant radiation, systemic chemotherapy, and or 
immunotherapy are not of benefit. Several reports show beneficial effect to immune 
response modifier Imiquimod, however, the safety and efficacy of this agent has not been 
adequately assessed (Brennan et al, 2011).  
9.1.2 BCC 
Development of frequent BCCs should prompt reduction in immunosuppression. The 
management otherwise is similar to that in non-immunocompromised patients. 
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9.1.3 MCC 
Although management of MCC is similar to that in non-immunocompromised patients, the 
overall prognosis is poorer in transplant patients as compared to the general population 
with 2 year survival of 44% versus 65-75%. Distant metastasis may regress temporarily with 
cyclosporine discontinuation (Brennan et al, 2011). 
9.2 Skin, melanoma 
Multiple strategies are required to treat melanoma including wide local excision with or 
without sentinel lymphadenectomy, and reduction of immunosuppression. 
9.3 KS 
Discontinuation of immunosuppression should be the first line of treatment as majority of 
patients with KS may show complete regression of the lesions. The disappearance of KS by 
reducing immunosuppression is about 17% with mucocutaneous disease and 16% with 
visceral involvement. Substitution of Sirolimus for cyclosporine has also been associated 
with complete regression (Stallone et al, 2005). Patients who do not regress spontaneously 
should be treated the same way as non-immunosuppressed patients are treated. In the 
CONVERT study, a randomized prospective study to evaluate the effect of conversion to 
sirolimus from CNI, displayed a significantly lower malignancy rate (3.8%) at 24 months 
compared with those who continued CNI based therapy (11%). An mTOR-inhibitor CNI-
free regimen should be considered for transplant recipients at high risk for cancer 
development and for those who develop malignancies over the post-transplant course 
(Alberú, 2010, & Schena, 2009). 
9.4 Anogenital carcinomas 
Anogenital Intra-epithelial neoplasia / in-situ carcinomas are treated with laser therapy, 
topical fluorouracil, or electrocautery. Reduction of immunosuppression is beneficial and 
may lead to regression of the in-situ lesions. Invasive carcinomas, on the other hand, require 
wide local excision with inguinal lymphadenectomy for tumors that are >1 mm thick. 
Adjuvant therapy is given to only selected patients. 
9.5 Bladder carcinomas 
9.5.1 Non-muscle invasive bladder carcinoma 
Bacillus Calmette-Guerin is still the only intravesical therapy that has shown a significant 
reduction in recurrence-free and possibly progression-free survival. 
9.5.2 Muscle-invasive bladder tumor 
The mean time between organ transplant and bladder tumor development is 2.8 and 4 years. 
Most patients presenting with muscle-invasive bladder carcinoma have extravesical disease 
or lymphadenopathy at the time of surgery. In general, there has been little to no 
improvement in the survival after radical cystectomy. A reasonable cancer-specific survival 
and renal allograft preservation is achieved after aggressive surgical therapy in only a few 
patients. (Wallerand et al, 2010). 
www.intechopen.com
 
Malignant Neoplasms in Kidney Transplantation 
 
197 
9.6 Other solid organ tumors 
The course of these malignancies is more aggressive than the general population and the 
outcome is mostly determined by the stage of tumor at the time of presentation. Visceral 
malignancies are treated with surgical intervention, chemotherapy, and radiation therapy. If 
chemotherapy is needed, azathioprine should be discontinued to avoid myelosuppression. 
Early invasive and in-situ carcinomas can be cured by surgery. The outcome is poor in 
advanced disease with majority of the patients dying within 1-2 months (Brennan et al, 
2011). 
9.7 Donor-derived tumors 
If the cancer is shown to be of donor origin, reduction of immunosuppression should 
theoretically lead to rejection of the tumor. This has been shown to be effective in PTLD but 
the data is not very supportive in other solid organ tumors. In RCC with no metastatic 
disease, total transplant nephrectomy is curative, however the patient has to go back to 
dialysis. Some authors suggest nephron sparing surgery in non-metastatic RCC that are 
located peripherally and are  < 4 cms in size. Recipients with metastatic RCC should be 
treated with transplant nephrectomy, reduction in immunosuppression, and immune 
therapy (Muruve & Shoskes, 2005). 
9.8 PTLD 
9.8.1 Reduction of immunosuppression 
The most important treatment modality for PTLD is reduction of immunosuppression 
which allows restoration of the natural T-cell mediated immune response against EBV-
infected B cells. The goal by reducing the immunosuppression is to find the correct dose that 
will allow restoration of the patient’s immune response against the PTLD without causing 
rejection of the transplanted organ. Transplant rejection occurs in approximately 39% of 
transplant recipients regardless of whether they respond to treatment or not. The risk of 
rejection also varies with the type of transplanted organ, with highest risk among heart and 
lung transplant recipients. The reduction of immunosuppression has no standard approach 
and it has to be individualized for each patient depending on various characteristics such as 
transplant type, relative risk of transplant rejection, extent and severity of PTLD, and 
selection of immunosuppressive agents. In general, MMF and azathioprine are discontinued 
first and the doses of CNI and steroids are reduced. There are several predictive factors to 
response to reduction of immunosuppression. Interestingly, EBV serostatus does not predict 
response and therefore this modality of treatment should be used for both EBV seronegative 
as well as EBV seropositive patients. Multiple factors are associated with poor response that 
include lactate dehydrogenase level of > 2.5 times the upper limit of normal, bulky disease, 
multiple visceral sites being involved, and organ dysfunction. Patients lacking these features 
show a response rate to reduction of immunosuppression as good as 89% (Morgans et al, 
2009). The vast majority of polyclonal lymphoproliferative lesions and EBV-related 
plasmacytomas show significant improvement or complete resolution by 
immunosuppression reduction. The response is best in patients with early onset disease in 
whom the level if immunosuppression is a major risk factor as compared to patients with 
late onset or extensive disease who are much less likely to benefit. One potential regimen for 
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patients who are severely ill and have extensive disease is to reduce prednisone and 
stopping all other immunosuppressive agents. For patients who are less severely ill and 
have only limited disease, one regimen is to reduce cyclosporine or tacrolimus and 
prednisone by at least 50% and the discontinuation of azathioprine or MMF. If necessary 
another 50% reduction of immunosuppression can be considered. Immunosuppressive 
regimens with the fewest possible toxic effects are desirable for transplant recipients. The 
ELITE-Symphony Study which is the largest prospective study in kidney transplantation 
evaluated the effects of standard dose versus low dose immunosuppression. The primary 
end point of the study was the estimated glomerular filtration rate and the secondary end 
points included acute rejection events and allograft survival. Over 3 years, daclizumab 
induction, MMF, steroids and low-dose tacrolimus proved highly efficacious, without the 
negative effects on renal function commonly reported for standard CNI regimens. (Ekberg 
et al, 2007, 2009). 
9.8.2 Antiviral prophylaxis 
Initially antiviral prophylaxis was used to eradicate EBV from the patient’s system thereby 
preventing reactivation of any latent infection and abnormal cellular proliferation that may 
lead to PTLD. Currently there is no supportive evidence of antiviral therapy efficacy for 
treatment of PTLD. The nucleoside analogues acyclovir and gancyclovir inhibit the 
replication of multiple members of herpes virus family including CMV and herpes simplex 
virus. Although theoretically these medications should be effective against EBV, in vivo they 
are not effective against EBV. These agents need intracellular phosphorylation by a viral-
encoded thymidine kinase which is not expressed in infected latent B cells. One approach to 
overcome this limitation is to use these agents in combination with arginine butyrate which 
induces the lytic phase of EBV gene expression and thus can induce expression of thymidine 
kinase. This may enable gancyclovir to be phosphorylated into its active form. Several 
studies are investigating the efficacy of these 2 agents used in combination in both solid 
organ as well as bone marrow transplant patients with PTLD and have shown moderate 
success (Morgans et al, 2009 & Friedberg et al, 2011).  
9.8.3 Local therapy 
Localized PTLD involving skin or a single GI lesion can be managed by surgery or radiation 
without the use of systemic therapy. This will spare the patient side effects of systemic 
therapy and withdrawal of immunosuppression. Local treatment in conjunction with 
immunosuppression reduction has resulted in very low PTLD-related mortality. Rituximab 
in combination with surgery or radiation has shown some success. Patients requiring 
palliative and emergent therapy for advanced disease can benefit from local field radiation 
therapy (Morgans, 2009). 
9.8.4 Anti-B-cell antibody 
Since most PTLDs are of B-cell origin, the use of medications that target B-cell antigens is 
proven beneficial with a reasonable response rate of 50-80%. In earlier studies the use of 
antiCD21 and antiCD24 has achieved complete response rates of 63% and long-term 
survival of 46%. However, in the past 10 years, more and more emphasis is on the use of 
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antiCD20, the rituximab in the treatment of CD20 positive PTLDs. AntiCD20 binds to B 
cells, induces clearance of cells and destruction by antibody-dependant complement-
mediated apoptosis. It may activate patient’s immune system against EBV-infected B cells 
helping destruction of tumor and preventing its recurrence. These proposed mechanisms of 
action would explain the better efficacy of rituximab in patients with PTLD than the usual 
NHLs. Risk factors for poor response to anti B-cell therapy include late onset PTLD (onset > 
1 years after transplantation), and involvement of CNS and multiple viscera. Rituximab has 
been reported to induce complete remission of PTLD in some patients with solid organ and 
bone marrow transplant. Early treatment with rituximab along with reduction of 
immunosuppression appears to be the evolving standard of care for CD20 positive PTLDs 
(Friedberg et al, 2011). Other anti-B-cell antibodies have not been fully evaluated 
systemically in PTLD. There are newer anti-CD20 antibodies such as tositumomab (anti-
CD20 coupled with radioactive iodine-131), ibitumomab (anti-CD20 with yttrium-90), 
epratuzumab (anti-CD22), and galiximab (antiCD 80) that are currently being investigated 
(Morgans et al, 2009).  
9.8.5 Cytotoxic chemotherapy 
For patients in whom reduction of immunosuppression is ineffective and who have rapidly 
progressive or life-threatening disease, chemotherapy can be used as an alternative or 
additional treatment. Several chemotherapy regimens similar to those used in NHLs are 
offered for treating patients with monoclonal PTLD such as cyclophosphamide with 
prednisone, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), dose-adjusted 
ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone), and other new 
regimens. Unfortunately although these chemotherapy agents are highly effective, they are 
associated with serious side-effects that significantly affect patient morbidity and mortality. 
Studies show that using CHOP after reduction of immunosuppression is associated with a 
complete remission rate of 63% and median disease-free survival of 10.5 years. The overall 
response rate of patients to rituximab is 68%. Patient with EBV-positive disease are more 
likely to respond to rituximab and achieve a complete response rate than those with EBV-
negative disease. Patients who received chemotherapy show an overall response rate of 
74%. Several factors limit the use of chemotherapy in PTLD. These  include suboptimal 
performance status, drug-to-drug interaction, high likelihood of infectious complications, 
and dose-limiting organ-dysfunction. Although the overall response rate is somewhat 
higher for chemotherapy, the associated toxic effects are significant. Approximately 50% of 
these patients get hospitalized for infections and about 6% eventually die of complications. 
The debate regarding when to use rituximab as opposed to chemotherapy and how to use 
them in combination is still ongoing with no consensus recommendations (Morgans et al, 
2009 & Friedberg et al, 2011). 
9.8.6 Cellular immunotherapy 
Cellular immunotherapy of PTLD involves reinfusion of T-cells into a recipient targeting the 
EBV-related lymphoma. T-cell targeting is HLA specific and EBV-specific and therefore 
cytotoxic T lymphocytes (CTL) must be HLA-matched to the recipient. Autologous pre-
transplant-harvested CTLs are shown to be effective in reducing the EBV viral loads. More 
recently several tissue banks have been storing EBV-specific CTLs for various HLA types. 
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The overall response rate after these infusions is close to 52% and the results are thought to 
have a better response at 6 months in patients receiving closest HLA-matched CTLs 
(Morgans et al, 2009).  
9.8.7 Retransplant 
Kidney transplant recipients can be treated with complete withdrawal of 
immunosuppression and even removal of transplanted organ as it is not a life-sustaining 
organ unlike heart and lung transplant. Successful treatment of PTLD can result in years of 
continous transplant function. Patients with transplant failure due to PTLD may safely go 
through re-transplantation after 1-2 years. In addition, relapse of PTLD after re-
transplantation only rarely occurs (Morgans et al, 2009). 
10. Conclusion 
Malignancy is a common cause of death after renal transplantation. Early detection and 
treatment of post-transplant malignancies is an important challenge. An even greater 
challenge is to prevent the development of these malignancies. Screening these patients for 
malignancies while they are on the waiting list for transplant and post-transplantation is 
crucial. It is also recommended to use the lowest planned doses of maintenance 
immunosuppressive medications by 2-4 months after transplantation, if there has been no 
acute rejection (Kasiske et al, 2010). The approach in these patients should start with 
preventive measures including minimizing immunosuppression, avoidance of carcinogenic 
factors such as ultraviolet radiation, avoidance of repeated exposure to depleting anti-
lymphocyte antibodies, and screening of donors and recipients for cancer. There is also 
growing interest in the potential antioncogenic characteristics of the immunosuppressive 
agent – mTOR inhibitor. Once malignancy is detected, it should be managed with specific 
therapy. Reducing CNI dose is a good first approach in patients who develop lymphoma, 
skin cancer, or KS. Substitution of CNI for mTOR can lead to complete regression of early, 
small, or low grade KS in renal transplant recipients. Regression of PTLD has also been 
reported with conversion of CNI by mTOR. Long term studies are needed confirm the 
beneficial effects of mTOR in regression of cancer in transplant recipients. 
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